Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G2BS
|
||||
| Former ID |
DNC004850
|
||||
| Drug Name |
2-(4-Methyl-piperazin-1-yl)-quinoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H17N3
|
||||
| Canonical SMILES |
CN1CCN(CC1)C2=NC3=CC=CC=C3C=C2
|
||||
| InChI |
1S/C14H17N3/c1-16-8-10-17(11-9-16)14-7-6-12-4-2-3-5-13(12)15-14/h2-7H,8-11H2,1H3
|
||||
| InChIKey |
HOMWNUXPSJQSSU-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine receptor 3A | Target Info | Inhibitor | [2] | |
| 5-hydroxy-tryptamine 3B receptor | Target Info | Inhibitor | [2] | ||
| Histamine H3 receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Serotonergic synapsehsa04726:Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | 5HT3 type receptor mediated signaling pathwayP04375:5HT3 type receptor mediated signaling pathway | ||||
| Reactome | Ligand-gated ion channel transportR-HSA-975298:Ligand-gated ion channel transportR-HSA-390650:Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Iron uptake and transportWP2670:Iron uptake and transportWP727:Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2005 Jan 13;48(1):306-11.2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. | ||||
| REF 2 | J Med Chem. 1999 May 6;42(9):1556-75.Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.